AVI BioPharma, a developer of RNA-based medicines, has named Peter Linsley as its CSO.
Linsley previously served as CSO of Regulus Therapeutics. Prior to that, he was executive director of cancer biology at Merck Research Laboratories.
Rosetta Genomics said that Kenneth Berlin, the firm's president and CEO, has stepped down from its board.
Berlin, who is replaced by board observer Brian Markison, stepped down in observance of good corporate governance practices pursuant to recommendations recently set forth in updated Israeli corporate law, the Rehovot, Israel-based company said.
His role as president and CEO is not affected.